Close

Beyond Air, Inc. (XAIR) Announces Delay in Approval Timeline for LungFit PH

Go back to Beyond Air, Inc. (XAIR) Announces Delay in Approval Timeline for LungFit PH

Beyond Air® Provides Regulatory Update for LungFit® PH

December 9, 2021 8:30 AM EST

GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN.

... More